Literature DB >> 3490285

Production of granulocyte-macrophage colony-stimulating factor by Abelson virus-induced tumorigenic mast cell lines.

S W Chung, P M Wong, G Shen-Ong, S Ruscetti, T Ishizaka, C J Eaves.   

Abstract

We have recently described a system that supports the development of continuously growing and tumorigenic cell lines after infection of individual multilineage hematopoietic colonies with Abelson murine leukemia virus (A-MuLV). We now provide definitive evidence that these transformed lines express features characteristic of mast cells. Although these lines have been maintained in some cases for more than a year in the absence of exogenous growth factors other than those present in fetal calf serum, colony formation could consistently after 2 months, and variably after 5 months, be shown to be increased several fold when pokeweed mitogen-stimulated spleen cell conditioned medium (CM) was added to the cultures. CM from the A-MuLV-transformed lines was then tested for its ability to stimulate hematopoietic colony formation by cells from both fetal and adult tissues. Four of four randomly selected cell lines produced factors that were active on erythropoietic, granulopoietic, and in some cases pluripotent progenitors. Removal of viral particles from the CM from one of the lines (27d1) by either heat inactivation or high-speed centrifugation did not alter the colony-stimulating activity detected. When CM from 27d1 cells was tested for its ability to stimulate the proliferation of interleukin 3 (IL3) granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent FDC-P1 cells, a positive result was obtained. This stimulatory activity was not reduced in the presence of neutralizing anti-IL 3 immunoglobulin (Ig), suggesting that the activity detected was GM-CSF and not IL 3. This was confirmed by the lack of expression of the IL 3 gene in 27d1 cells as determined by Northern analysis of 27d1 cell RNA. Furthermore, S1 analysis of mRNA from 27d1 cells as well as two other lines indicated that the GM-CSF gene in all three was transcriptionally active. Taken together, these data suggest that A-MuLV transformation of normal mast cells or their precursors under certain conditions commonly activates the production of GM-CSF.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490285

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Chronic myeloproliferative disease induced by site-specific integration of Abelson murine leukemia virus-infected hemopoietic stem cells.

Authors:  X D Han; P M Wong; S W Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 2.  Mast cells as sources of cytokines, chemokines, and growth factors.

Authors:  Kaori Mukai; Mindy Tsai; Hirohisa Saito; Stephen J Galli
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

3.  High-efficiency identification of genes by functional analysis from a retroviral cDNA expression library.

Authors:  B Y Wong; H Chen; S W Chung; P M Wong
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

4.  Retrovirus-mediated transfer and expression of the interleukin-3 gene in mouse hematopoietic cells result in a myeloproliferative disorder.

Authors:  P M Wong; S W Chung; C E Dunbar; D M Bodine; S Ruscetti; A W Nienhuis
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

5.  Leukemia initiated by hemopoietic stem cells expressing the v-abl oncogene.

Authors:  S W Chung; P M Wong; H Durkin; Y S Wu; J Petersen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

6.  Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines.

Authors:  P R Burd; H W Rogers; J R Gordon; C A Martin; S Jayaraman; S D Wilson; A M Dvorak; S J Galli; M E Dorf
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

Review 7.  Mast Cell Responses to Viruses and Pathogen Products.

Authors:  Jean S Marshall; Liliana Portales-Cervantes; Edwin Leong
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.